Balversa medication
Ended Awarded
- Contract number
- 36C24122N0219
- Awardee
-
Janssen Biotech Inc. UEI NVYMGFA53MN7
- Awarding agency
-
Veterans Integrated Service Network 1
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $11,318
Award facts
- Contract value 100% obligated
- $11,317.97 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Carrollton, TX 75010, USA
Award details come from SAM.gov/FPDS.
About this award
This federal contract award is for the supply of BALVERSA (erdafitinib), a cancer treatment medication, to the Department of Veterans Affairs (VA) through the Veterans Health Administration (VHA). The prime contractor is Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer that specializes in biologic therapies.
The contract is a Blanket Purchase Agreement (BPA) established in August 2020, with a ceiling value of $3.7 million and a period of performance through July 2024. This BPA allows VA buying offices to place firm fixed price call orders for BALVERSA and other oncology medications such as Belzutifan (WELIREG). The contract is not set aside for any specific business type.
Additionally, Janssen Biotech holds a $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) with the VA, which serves as the parent vehicle for many of the company's delivery orders. This FSS contract enables the VA to efficiently procure a wide range of pharmaceutical products to support its comprehensive healthcare programs for veterans.
Quick answers
Who was awarded contract 36C24122N0219?
36C24122N0219 was awarded to Janssen Biotech Inc. by Veterans Integrated Service Network 1 (Veterans Health Administration) on December 28, 2021.
How much is contract 36C24122N0219 worth?
The government has obligated $11,318 on 36C24122N0219.
Is contract 36C24122N0219 an order under another contract?
Yes. 36C24122N0219 is a BPA call under 36F79719D0217-36E79720A0015, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24122N0219 competed?
The extent of competition for 36C24122N0219 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award